BT200 (inferred)
Thrombotic/Hematologic Disorder (targets vWF A1 domain)
Pre-clinicalActive
Key Facts
Indication
Thrombotic/Hematologic Disorder (targets vWF A1 domain)
Phase
Pre-clinical
Status
Active
Company
About Guardian Therapeutics
Guardian Therapeutics is a private, pre-revenue biotech pioneering the development of aptamer drug conjugates (ApDCs) and other aptamer therapeutics. The company's platform enables rapid discovery of therapeutic aptamers with high affinity and stability, targeting a broad pipeline across hematology, gastroenterology, dermatology, and oncology. Led by co-founders CEO Jim Gilbert, MD, and CSO Shuhao Zhu, PhD, the company is advancing its platform and pipeline from its headquarters in Lowell, Massachusetts. Guardian's strategy positions it to capitalize on the potential advantages of aptamers over traditional antibody-based therapies.
View full company profile